Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 2/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.43 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9001749 | 0.87 | CCR3 (0.51) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL3840449 | 0.87 | CCR3 (0.51) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL17103472 | 0.86 | CCR3 (0.47) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL17103469 | 0.86 | CCR3 (0.47) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL1636764 | 0.86 | CCR3 (0.43) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL29449914 | 0.85 | CCR3 (0.46) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL17103611 | 0.81 | CCR3 (0.44) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL17103610 | 0.81 | CCR3 (0.44) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL14492207 | 0.81 | ACHE (0.51) | CCR3CCR5ABL1RIN1USP30 | |
| SCHEMBL7403462 | 0.81 | CCR3 (0.47) | CCR3CCR5ABL1RIN1USP30 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932421-B2 | diabetes or obesity; polycystic ovarian disease, an eating disorder, craniopharyngioma, Prader-Willi syndrome, Frohlich's syndrome, hyperlipidemia, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, low HDL levels, high HDL levels, hyperglycemia, insulin resistance, hyperinsulinemia, Cushing's | AMGEN INC. (US) | 2011-04-26 | — | — | US | claimed |
| EP-2121580-A2 | N-CYCLOHEXYL BENZAMIDES AND BENZENEACETAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASES | Amgen Inc. (US) | 2009-11-25 | — | — | EP | claimed |
| US-20080221175-A1 | N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases | AMGEN INC. | 2008-09-11 | — | — | US | claimed |
| WO-2008088540-A2 | N-CYCLOHEXYL BENZAMIDES AND BENZENEACETAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2008-07-24 | — | — | WO | claimed |
| US-7932421-B2 | diabetes or obesity; polycystic ovarian disease, an eating disorder, craniopharyngioma, Prader-Willi syndrome, Frohlich's syndrome, hyperlipidemia, dyslipidemia, hypercholesterolemia, hypertriglyceridemia, low HDL levels, high HDL levels, hyperglycemia, insulin resistance, hyperinsulinemia, Cushing's | AMGEN INC. (US) | 2011-04-26 | — | — | US | disclosed |
| EP-2121580-A2 | N-CYCLOHEXYL BENZAMIDES AND BENZENEACETAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASES | Amgen Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080221175-A1 | N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases | AMGEN INC. | 2008-09-11 | — | — | US | disclosed |
| WO-2008088540-A2 | N-CYCLOHEXYL BENZAMIDES AND BENZENEACETAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASES | AMGEN INC. (US) | 2008-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221175-A1 | N-cyclohexyl benzamides and benzeneacetamides as inhibitors of 11-beta-hydroxysteroid dehydrogenases | HSD11B1, HSD3B1, HSD3B2 | CCR3 1856/4885CCR5 1611/4885ITGB3 4035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.